Braveheart Bio, Inc. (Nasdaq: BRVE) reported unaudited financial results for the second quarter ended June 30, 2026, and provided an update on its clinical-stage biopharmaceutical operations. The company announced that its cash and cash equivalents totaled $122.8 million as of June 30, 2026, an increase from $89.2 million at the end of 2025. The filing notes that this balance does not include the proceeds from the company’s initial public offering (IPO), which closed in August 2026.
Braveheart Bio completed its IPO in August 2026, issuing an aggregate of 24,437,500 shares of common stock at $18.00 per share. This transaction resulted in gross proceeds of approximately $439.9 million and net proceeds of about $404.5 million after deducting underwriting discounts and offering expenses. Including these IPO proceeds, the company’s cash and cash equivalents would have been approximately $527.3 million on an as-adjusted basis as of June 30, 2026.
Regarding operating expenses, Research and Development (R&D) costs were $11.1 million for the three months ended June 30, 2026, compared to $0.0 million for the same period in 2025. General and Administrative (G&A) expenses were $4.8 million for the quarter, compared to less than $0.1 million in the prior year. The company reported a net loss of $15.0 million for the quarter, with a net loss attributable to common stockholders of $18.6 million, or $2.51 per share. This loss included a non-cash deemed dividend of $3.6 million related to the issuance of Series A preferred stock in April 2026.
On the business development front, Braveheart Bio initiated the LIONHEART-HCM Phase 3 trial in May 2026. This multi-region, multi-center, randomized, double-blind, active-comparator-controlled trial aims to evaluate the efficacy and safety of BHB-1893 compared to metoprolol in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The company stated that sites are being activated and patients are screening for the study, with an expectation to dose the first patient in 2026. Additionally, Braveheart Bio has an active U.S. Investigational New Drug (IND) application and expects to initiate the NOBLEHEART-HCM Phase 3 study in non-obstructive HCM in the first half of 2027.
The company also highlighted results from a Phase 2 trial in non-obstructive HCM, which were presented at the 2026 annual meeting of the Heart Failure Association of the European Society of Cardiology. The trial showed statistically significant reductions in cardiac biomarkers and improvements in myocardial relaxation and diastolic function compared to placebo. Furthermore, Braveheart Bio completed a Series A preferred stock financing in April 2026, issuing 60,000,000 shares at $1.00 per share for gross proceeds of $60.0 million.
